SCHEMBL13622745

SCHEMBL13622745

CC(C)(C)OC(=O)Nc1cccc(CCc2cc(Nc3nc(Cl)ncc3Cl)ccc2NC(=O)OC(C)(C)C)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.43
STK17B O94768 1/20 0.43
STK17A Q9UEE5 1/20 0.43
CDK1 P06493 1/20 0.42
MET P08581 1/20 0.42
EGFR P00533 7/20 0.41
SRC P12931 1/20 0.41
SIRT2 Q8IXJ6 1/20 0.40
AURKA O14965 1/20 0.40
RPS6KB1 P23443 1/20 0.40
BCL6 P41182 1/20 0.39
BRD4 O60885 2/20 0.39
BTK Q06187 2/20 0.38
ERBB2 P04626 1/20 0.38
ERBB3 P21860 1/20 0.38
ERBB4 Q15303 1/20 0.38
JAK3 P52333 1/20 0.38
P2RX7 Q99572 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1026903 0.96 STK17B (0.41) SYKSTK17BSTK17ACDK1MET
SCHEMBL13623080 0.92 EGFR (0.43) SYKCDK1EGFRSRCSIRT2
SCHEMBL13623076 0.92 SYK (0.54) SYKCDK1EGFRSRCSIRT2
SCHEMBL1027969 0.90 EGFR (0.43) SYKSTK17BSTK17ACDK1MET
SCHEMBL13622748 0.90 STK17B (0.43) SYKSTK17BSTK17ACDK1MET
SCHEMBL1025626 0.89 SYK (0.42) SYKSTK17BSTK17ACDK1MET
SCHEMBL4338777 0.89 EGFR (0.42) SYKCDK1EGFRSRCSIRT2
SCHEMBL1025607 0.88 STK17B (0.39) SYKSTK17BSTK17ACDK1MET
SCHEMBL4341114 0.88 SYK (0.50) SYKEGFRSIRT2BTK
SCHEMBL13623059 0.86 STK17B (0.46) SYKSTK17BSTK17ACDK1MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK SYK 46/4885STK17B 139/4885STK17A 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.